Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

According to a new feature by the Washington Post, approximately 16 million American adults are on GLP-1 drugs such as ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Wegovy, a weight loss drug, is gaining popularity for its effectiveness, but experts emphasize that it's most successful when ...

Research indicates GLP-1 receptor agonists, like Ozempic, may elevate testosterone levels in men while promoting weight loss.

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

Medication paired with behavioral change support gives employers the opportunity to provide a more well-rounded approach to ...

A new study suggests that this side effect of drugs like Ozempic may relieve men of the surprising ailment that affects ...

According to a survey by the World Obesity Foundation, obesity is on the rise in the United Arab Emirates, where an estimated ...